ReviewNature reviews. Cardiology2022
Epicardial adipose tissue in contemporary cardiology.
Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 432 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intramyocellular Lipid Compartments After Glucagon-like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes - Rebalancing the Fat Content of the Heart and Muscles
MRI of Epicardial Adipose Tissue Composition: Development of Methods and Application to Heart Failure With Preserved Ejection Fraction
Who cites it
432 citing papers in PubMed, 3 syntheses or guidelines pooled it, 684 citations in OpenAlex.
- Precision or Paradox? AI-Driven Adiposity Imaging in Women With Overweight and Obesity: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- The Role of Echocardiography in the Assessment of Epicardial Adipose Tissue: A Systematic Review and Meta-analysis.Current obesity reports · 2026Pooled it
- Elevated Epicardial Adipose Tissue and Ischemic Stroke Risk: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Abnormal "Frontiers in cardiovascular medicine · 2026Trial
- Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.Diabetes, obesity & metabolism · 2025Trial
- Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.Cardiovascular diabetology · 2025Trial
- Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026.Obesity pillars · 2026Review
- Epicardial and pericardial adipose tissue: anatomy, physiology, imaging, segmentation, and treatment effects.The British journal of radiology · 2026Review
- Standardized MRI-Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography.Journal of magnetic resonance imaging : JMRI · 2026Article
- Prognostic value of epicardial and pericardial adipose tissue in patients with chronic heart failure.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026Article
- SURPASS-CVOT and the Emerging Biology of Cardiometabolic Benefit.Diabetes, obesity & metabolism · 2026Article
- Editorial for "Standardized MRI-Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography".Journal of magnetic resonance imaging : JMRI · 2026Article
- The Cardio-Renal-Hepatic Axis in MASLD. Role of BDNF, NGF, and Metabolic Cross-Talk.Current hypertension reports · 2026Review
- Epicardial Adipose Tissue Shows No Significant Incremental Value for Discriminating Coronary Artery Disease in Adults Aged 80 Years and Older: A Machine Learning Analysis.Journal of cardiovascular development and disease · 2026Article
- EAT Thickness and BAT-Related Thermogenesis: Dual Imaging Phenotypes Associated with Hepatic Steatosis Severity in MASLD.Diagnostics (Basel, Switzerland) · 2026Article
- Extracellular Vesicles in Cardiovascular Disease: Intercellular Signaling, Liquid Biopsy Biomarkers, and Therapeutic Translation.Circulation research · 2026Review
- Adipose-Myocardial Border in Atrial Fibrillation.Circulation research · 2026Article
- Prognostic impact of epicardial fat volume, anatomical and functional imaging across the cardiovascular risk spectrum in patients with suspected coronary artery disease: a single-center retrospective cohort study.Quantitative imaging in medicine and surgery · 2026Article
- Peroxisomal dysfunction in cardiac adipose tissue is involved in obesity-associated cardiac hypertrophy.Journal of advanced research · 2026Article
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
372 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and unobstructed proximity to the heart and has a transcriptome and secretome very different from that of other fat depots. EAT has physiological and pathological properties that vary depending on its location. It can be highly protective for the adjacent myocardium through dynamic brown fat-like thermogenic function and harmful via paracrine or vasocrine secretion of pro-inflammatory and profibrotic cytokines. EAT is a modifiable risk factor that can be assessed with traditional and novel imaging techniques. Coronary and left atrial EAT are involved in the pathogenesis of coronary artery disease and atrial fibrillation, respectively, and it also contributes to the development and progression of heart failure. In addition, EAT might have a role in coronavirus disease 2019 (COVID-19)-related cardiac syndrome. EAT is a reliable potential therapeutic target for drugs with cardiovascular benefits such as glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter 2 inhibitors. This Review provides a comprehensive and up-to-date overview of the role of EAT in cardiovascular disease and highlights the translational nature of EAT research and its applications in contemporary cardiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.